Navigation Links
ACS Green Chemistry Institute Pharmaceutical Roundtable award goes to Scottish chemist
Date:4/29/2010

WASHINGTON, April 29, 2010 The American Chemical Society Green Chemistry Institute (ACS GCI) Pharmaceutical Roundtable has awarded its 2010 research grant to Scottish chemist David Cole-Hamilton, Ph.D., for making great strides in expanding green chemistry and engineering practices in the global pharmaceutical industry. Cole-Hamilton will use the one-year $150,000-grant to further his study of the hydrogenation of amides to amines, resulting in improved benefits for the environment. He is the Irvine Professor of Chemistry, EaStCHEM, University of St. Andrews, Scotland.

Cole-Hamilton's research seeks to provide safer and environmentally friendly solutions to convert amides to amines, important in the development of many pharmaceutically active compounds. Conversion of the amide to the amine is usually conducted using a metallic hydride source such as sodium borohydride or lithium aluminum hydride.

The reactions are stoichiometric and large amounts of aluminum- or boron- containing side products are formed. Requiring separation from the desired amine product, these side products are usually disposed of in a landfill. The Roundtable identified greener amide reductions as one of the 12 key green chemistry research areas important for the pharmaceutical industry.

Cole-Hamilton's study will build upon exciting preliminary results, which proved it should be possible to use catalytic amide hydrogenation, which would only give water as a side product. If the catalyst is very active or can be recycled, there is no need for any significant waste from this reaction.

Since 2007 the grant program has awarded $800,000 toward research in the 12 key green chemistry research areas. All funding is made possible by a partnership between the ACS GCI and an alliance of major pharmaceutical companies Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Codexis, Dr. Reddy's, DSM Pharmaceutical Products, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Novartis, Pfizer, and Roche.

Under the leadership of Cole-Hamilton, the St. Andrews group will collaborate with members of the Roundtable to improve the technology and allow it to be introduced widely and without restriction into the pharmaceutical industry. Major targets will be lowering the temperature and especially the pressure at which reactions are carried out, improving the selectivity toward the desired amines (currently 85-90 percent, with alcohols as the side products) and exploring scope and the functional group tolerance of the reaction.


'/>"/>

Contact: Julie Manley
j_manley@acs.org
815-325-4974
American Chemical Society
Source:Eurekalert  

Related biology news :

1. Study gives green light to plants’ role in global warming
2. Georgia Powers Green Energy Program Redesigned to Include More Solar Power
3. New York City Regional Extension Center Selects Greenway
4. New evidence that green tea may help fight glaucoma and other eye diseases
5. From bacteria to electricity: The future of green energy
6. Demystifying yield fluctuations for greenhouse tomatoes
7. Solid-state illuminator reduces nitrates in leafy green vegetables
8. Global study shows health joins green as business strategy
9. Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet
10. Spray application rate, equipment affect pest management in greenhouse ivy plants
11. More maize ethanol may boost greenhouse gas emissions
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
ACS Green Chemistry Institute Pharmaceutical Roundtable award goes to Scottish chemist
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... San Diego, CA (PRWEB) , ... June 27, 2016 , ... ... mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient ... and their care circle with the physician and clinical trial team. , Using the ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology: